Olpasiran & Lp(a) siRNA Pipeline — PatSnap Eureka
Olpasiran & the Lp(a) siRNA Race: Amgen, Eli Lilly, and AstraZeneca in ASCVD
Lipoprotein(a) is one of cardiovascular medicine's most stubborn unmet needs — genetically determined, largely unresponsive to existing therapies, and present in roughly 20% of the global population at high-risk levels. GalNAc-conjugated siRNA is changing that equation. Track the patent positions, clinical milestones, and competitive dynamics of olpasiran, zerlasiran, lepodisiran, and pelacarsen with PatSnap Eureka.
Why Lp(a) Has Resisted Treatment — Until Now
Lipoprotein(a) — Lp(a) — is a low-density lipoprotein-like particle carrying apolipoprotein(a), encoded by the LPA gene. Elevated Lp(a) is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, stroke, and aortic stenosis. Unlike LDL cholesterol, Lp(a) levels are largely unresponsive to diet and most existing lipid-lowering therapies, making dedicated Lp(a)-lowering agents a major unmet clinical need.
Small interfering RNA (siRNA) therapeutics offer a fundamentally different approach: rather than blocking a protein after it is made, they silence the LPA gene at the mRNA level inside hepatocytes — the liver cells where apolipoprotein(a) is almost exclusively synthesised. The result is sustained, deep suppression of Lp(a) production from a single subcutaneous injection, with effects lasting weeks to months. This durability is critical for patient adherence in a chronic cardiovascular risk setting.
GalNAc (N-acetylgalactosamine) conjugation supercharges this delivery by targeting the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes. GalNAc-siRNA conjugates achieve high local drug concentrations precisely where Lp(a) is made, enabling potent gene silencing without systemic delivery challenges. The patent landscape around GalNAc-siRNA delivery is dominated by Alnylam Pharmaceuticals' foundational IP, which underpins multiple competitor programmes through licensing arrangements — a critical freedom-to-operate consideration for any entrant.
According to World Health Organization cardiovascular disease data, ASCVD remains the leading cause of death globally, and a substantial subset of residual risk in treated patients is attributable to elevated Lp(a) — a population that existing statin and PCSK9 inhibitor regimens do not adequately address.
Lp(a) Pipeline by the Numbers
Clinical efficacy and pipeline development stage data for the leading Lp(a)-targeting agents, derived from published trial results and patent analysis via PatSnap Eureka.
Lp(a) Reduction from Baseline — Phase 2 Peak Dose
All three siRNA candidates achieve >90% Lp(a) reduction, far exceeding PCSK9 inhibitors (~25%) and niacin (~20–30%).
Lp(a)-Lowering Pipeline by Development Stage
Two agents have reached Phase 3 (olpasiran and pelacarsen); two remain in Phase 2 (zerlasiran, lepodisiran), with muvalaplin representing a distinct oral small-molecule approach.
Olpasiran, Zerlasiran, Lepodisiran & Pelacarsen: Agent Profiles
Each agent in the Lp(a) pipeline takes a distinct approach to mechanism, dosing, and clinical positioning. Understanding these differences is essential for IP strategy and competitive forecasting.
Olpasiran — The Phase 3 Pioneer
Olpasiran is a GalNAc-conjugated siRNA developed by Amgen that targets the LPA gene in hepatocytes, silencing apolipoprotein(a) production at the mRNA level. The OCEAN(a)-DOSE Phase 2 trial demonstrated Lp(a) reductions of more than 95% from baseline at the 225 mg every-12-weeks dose. The ongoing OCEAN(a) Outcomes Phase 3 trial evaluates whether these reductions translate into fewer major adverse cardiovascular events (MACE) in patients with established ASCVD and elevated Lp(a). Amgen's patent portfolio covers specific siRNA sequences, GalNAc linker chemistry, and method-of-treatment claims in cardiovascular indications. Freedom-to-operate analysis must account for Alnylam's foundational GalNAc-siRNA platform IP licensed to Amgen.
OCEAN(a) Outcomes — Phase 3 MACE trial ongoingZerlasiran (SLN360) — Quarterly to Biannual Dosing
Zerlasiran, formerly SLN360, was developed by Silence Therapeutics and licensed to Eli Lilly in a significant cardiovascular RNA therapeutics deal. Phase 2 data demonstrated Lp(a) reductions exceeding 90% at the 300 mg dose administered every 24 weeks — a twice-yearly regimen that could offer a patient adherence advantage. Silence Therapeutics' proprietary AtuRNAi chemistry and GalNAc conjugation platform underpin zerlasiran's IP position, and Lilly's licensing deal signals the commercial value assigned to this asset. The agent is advancing toward Phase 3 cardiovascular outcomes evaluation.
>90% Lp(a) reduction · 300 mg Q24W in Phase 2Lepodisiran — Lilly's Internal siRNA Programme
Lepodisiran is Eli Lilly's internally developed GalNAc-siRNA candidate targeting the LPA gene. Phase 2 data showed Lp(a) reductions exceeding 94% from baseline, positioning it alongside olpasiran in depth of effect. Lilly is therefore running parallel Lp(a) programmes — lepodisiran (internal siRNA) and zerlasiran (licensed from Silence Therapeutics) — reflecting a portfolio strategy to hedge across different siRNA chemistries and IP estates. This dual-programme approach raises important questions about which asset Lilly will advance to a pivotal outcomes trial and how the two programmes' patent positions interact. Lepodisiran's Phase 2 data were published in the New England Journal of Medicine.
>94% Lp(a) reduction · NEJM Phase 2 publicationPelacarsen — ASO Approach in Lp(a)HORIZON
Pelacarsen is an antisense oligonucleotide (ASO) — mechanistically distinct from siRNA — developed by Ionis Pharmaceuticals and partnered with AstraZeneca for cardiovascular development and commercialisation. The Lp(a)HORIZON Phase 3 cardiovascular outcomes trial is ongoing, making pelacarsen the only non-siRNA agent in a pivotal Lp(a) outcomes study. ASOs work by recruiting RNase H to degrade LPA mRNA, a different silencing mechanism from RISC-mediated siRNA cleavage. AstraZeneca's involvement reflects its broader cardiovascular RNA therapeutics strategy and its partnership with data-driven R&D platforms for pipeline acceleration. Pelacarsen requires weekly subcutaneous dosing, a potential disadvantage versus quarterly siRNA regimens.
Lp(a)HORIZON Phase 3 · Weekly subcutaneous dosingLp(a) Pipeline: Mechanism, Dosing & IP at a Glance
A structured comparison of the five clinical-stage Lp(a)-lowering agents across the dimensions most relevant to IP strategy, clinical positioning, and competitive forecasting.
| Agent | Sponsor(s) | Mechanism | Dosing Interval | Peak Lp(a) Reduction | Development Stage |
|---|---|---|---|---|---|
| Olpasiran | Amgen | GalNAc-siRNA (LPA) | Q12W (225 mg) | >95% DEEPEST | Phase 3 |
| Pelacarsen | Ionis / AstraZeneca | GalNAc-ASO (LPA) | Weekly | ~80% | Phase 3 |
| Lepodisiran | Eli Lilly | GalNAc-siRNA (LPA) | TBD (Phase 2) | >94% | Phase 2 |
| Zerlasiran | Silence / Eli Lilly | GalNAc-siRNA (LPA) | Q24W (300 mg) | >90% | Phase 2/3 |
Need deeper competitive intelligence on Lp(a) siRNA patents?
PatSnap Eureka surfaces assignee portfolios, claim maps, and prosecution history in seconds.
Key Patent & Competitive Dynamics in the Lp(a) siRNA Space
Critical IP considerations and strategic signals for R&D teams, IP counsel, and business development professionals tracking this pipeline.
GalNAc Platform IP — The Foundational Layer
Alnylam Pharmaceuticals holds foundational patents on GalNAc-siRNA conjugation chemistry, including the ASGPR-targeting delivery mechanism that underpins olpasiran, zerlasiran, and lepodisiran. All three siRNA programmes operate under licensing arrangements with Alnylam. Understanding the scope and expiry timeline of these platform patents is essential for assessing the competitive IP landscape and potential generic/biosimilar entry windows. The European Patent Office and USPTO patent databases hold the primary prosecution history for these foundational claims.
Sequence-Level Differentiation — Where FTO Risk Lives
Beyond the GalNAc platform layer, each programme holds composition-of-matter patents on its specific siRNA duplex sequences targeting LPA mRNA. The degree of sequence overlap between olpasiran, lepodisiran, and zerlasiran — and the breadth of each programme's sequence claims — determines the freedom-to-operate risk profile for new entrants. PatSnap Eureka's AI-powered sequence analysis can map claim coverage across all three programmes simultaneously, identifying white-space regions and potential infringement vectors that manual review would miss.
Eli Lilly's Dual-Programme Strategy
Eli Lilly's simultaneous advancement of both lepodisiran (internal) and zerlasiran (licensed from Silence Therapeutics) creates an unusual competitive dynamic. The two programmes target the same gene with similar mechanisms but different siRNA chemistries and IP estates. Lilly's portfolio strategy may reflect a hedge against clinical attrition, IP risk, or differentiated dosing profiles. For competitors and IP analysts, monitoring which programme Lilly advances to a Phase 3 outcomes trial — and whether it terminates or out-licenses the other — will be a key signal for the Lp(a) market structure through 2030.
OCEAN(a) Outcomes — The Pivotal Data Event
The OCEAN(a) Outcomes Phase 3 trial is the most consequential near-term data event in the Lp(a) space. If olpasiran demonstrates a statistically significant reduction in MACE, it will validate the Lp(a)-lowering hypothesis for the entire field — benefiting all pipeline programmes — and simultaneously establish Amgen's first-mover commercial advantage. A neutral result would cast doubt on the causal role of Lp(a) in residual cardiovascular risk and could reset the competitive landscape. Tracking OCEAN(a) trial registry updates via ClinicalTrials.gov and PatSnap's clinical intelligence tools is essential for any stakeholder in this space.
Olpasiran & Lp(a) siRNA Pipeline — Key Questions Answered
Olpasiran is a GalNAc-conjugated small interfering RNA (siRNA) developed by Amgen that targets the LPA gene in hepatocytes, silencing the production of apolipoprotein(a) — the defining protein of Lp(a) particles. By blocking Lp(a) synthesis at the mRNA level, olpasiran achieves sustained and deep reductions in circulating Lp(a) concentrations with infrequent subcutaneous dosing.
Lipoprotein(a) — Lp(a) — is a low-density lipoprotein-like particle carrying apolipoprotein(a). Elevated Lp(a) is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, stroke, and aortic stenosis. Unlike LDL cholesterol, Lp(a) levels are largely unresponsive to diet and most existing lipid-lowering therapies, making dedicated Lp(a)-lowering agents a major unmet need.
The principal competitors are zerlasiran (formerly SLN360), developed by Silence Therapeutics and licensed to Eli Lilly, and lepodisiran, another siRNA candidate in Eli Lilly's pipeline. AstraZeneca is pursuing the space through its partnership with Ionis Pharmaceuticals on pelacarsen (an antisense oligonucleotide) and through broader cardiovascular RNA therapeutics collaborations. Muvalaplin, developed by Eli Lilly, is a small-molecule oral inhibitor of Lp(a) assembly that represents a mechanistically distinct approach.
The OCEAN(a)-DOSE Phase 2 trial demonstrated that olpasiran reduced Lp(a) concentrations by more than 95% from baseline at the highest dose tested (225 mg every 12 weeks), with reductions sustained over the dosing interval. The ongoing OCEAN(a) Outcomes trial is a Phase 3 cardiovascular outcomes study evaluating whether these Lp(a) reductions translate into reduced rates of major adverse cardiovascular events (MACE) in patients with established ASCVD and elevated Lp(a).
GalNAc (N-acetylgalactosamine) conjugation enables targeted delivery of siRNA to hepatocytes via the asialoglycoprotein receptor (ASGPR), which is highly expressed on liver cells. Because apolipoprotein(a) is synthesised almost exclusively in the liver, GalNAc-siRNA conjugates achieve high local drug concentrations at the site of Lp(a) production, enabling potent and durable gene silencing with subcutaneous administration and infrequent dosing schedules — typically quarterly or less.
The Lp(a) siRNA patent landscape encompasses several overlapping domains: composition-of-matter claims on specific siRNA sequences targeting LPA mRNA; GalNAc conjugation chemistry and linker patents held broadly by Alnylam Pharmaceuticals; formulation and delivery patents; and method-of-treatment patents covering Lp(a) reduction in ASCVD populations. Freedom-to-operate analysis is complex given Alnylam's foundational GalNAc-siRNA platform IP, which underlies multiple competitor programmes through licensing arrangements.
Still have questions about the Lp(a) siRNA pipeline? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka About Lp(a)Accelerate Your Lp(a) & ASCVD Drug Intelligence
From olpasiran's OCEAN(a) trial to Alnylam's GalNAc IP estate — PatSnap Eureka gives R&D teams, IP counsel, and business development professionals the patent and clinical intelligence to move faster and smarter in the Lp(a) siRNA race. Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D.
References
- New England Journal of Medicine — Lepodisiran Phase 2 clinical trial publication; olpasiran OCEAN(a)-DOSE Phase 2 results.
- ClinicalTrials.gov — OCEAN(a) Outcomes Phase 3 trial registry; Lp(a)HORIZON Phase 3 trial registry; zerlasiran Phase 2 trial registrations.
- European Patent Office (EPO) — GalNAc-siRNA platform patent filings; Alnylam, Amgen, Silence Therapeutics, and Ionis patent prosecution records.
- National Institutes of Health (NIH) — Lp(a) as an independent cardiovascular risk factor; LPA gene biology and apolipoprotein(a) structure references.
- World Health Organization (WHO) — Global cardiovascular disease burden statistics; ASCVD as leading cause of mortality.
- PatSnap Innovation Intelligence Platform — Global patent database, pipeline analytics, and AI-powered drug intelligence used throughout this analysis.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Clinical efficacy figures reflect published Phase 2 data at peak doses tested; outcomes data from Phase 3 trials are pending.
PatSnap Eureka searches patents and research to answer instantly.